Quarterly ResultAug 13, 2026, 05:09 PM
Satellos Bioscience Q2 Loss $11.7M; SAT-3247 Gets FDA Fast Track
AI Summary
Satellos Bioscience reported a net loss of $11.7 million for Q2 2026, increasing from $5.6 million in Q2 2025, with R&D expenses significantly rising to $9.6 million. The company announced that its drug candidate, SAT-3247, received FDA Fast Track Designation for Duchenne muscular dystrophy (DMD). Interim data from the TRAILHEAD Phase 2 adult DMD study showed signs of muscle regeneration and improved quality of life, with data from the BASECAMP pediatric study expected in Q4 2026. Satellos maintains a strong financial position with $61.8 million in cash and investments, providing runway through 2027.
Key Highlights
- Q2 2026 net loss was $11.7 million, up from $5.6 million in Q2 2025.
- Six-month 2026 net loss was $21.5 million, up from $11.7 million in 2025.
- Cash, cash equivalents, and short-term investments totaled $61.8 million as of June 30, 2026.
- R&D expenses for Q2 2026 increased to $9.6 million from $4.4 million in Q2 2025.
- SAT-3247 received FDA Fast Track Designation for Duchenne muscular dystrophy (DMD).
- TRAILHEAD Phase 2 adult DMD study showed muscle fat reduction and increased effort.
- BASECAMP Phase 2 pediatric DMD study data is anticipated in Q4 2026.
Price Impact
More from MSLE